Authors:
Robert N.J., Anthony S.P., Arguello D., Jameson G.S., Northfelt D.W., Jahanzeb M., Petricoin E., Pierobon M., Dunetz B., Liotta L.A., Loesch D.M.
Background
There is an unmet need for rapid assays predictive of efficacy for specific chemotherapy agents. In particular, for those patients with metastatic disease that have progressed on prior therapies. Newer multi-omic analysis can be performed on a single biopsy specimen and with rapid turn-around-time allowing greater clinical utility.
Download PublicationCookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |